Aptys Pharmaceuticals has completed a third financial round dedicated to the development of its innovative product for the treatment of moderate to severe pain.

« This round demonstrates that our economical mix model is successful» says François Boutignon, president of Aptys Pharmaceuticals. « Indeed, Aptys grew on the basis of its know-how and expertise dedicated to its pharmaceutical and biotech clients as well as to its own developments. We are glad to have found a financial partner coming from the pharmaceutical industry who recognized the pertinence of our strategy and agreed to follow us while we keep the control of corporate development».